Scientists Reaffirm HIV Capsid as Potent Drug Target, Overcoming Challenges of Viral Resistance
Researchers have confirmed that the HIV capsid—the protein shell protecting the virus's genetic material—is an excellent target for long-acting antiretroviral therapy. A new drug, Lenacapavir, the first capsid-based inhibitor, has shown high efficacy in clinical trials. Unlike older drugs, Lenacapavir is administered as a subcutaneous injection once every six months, forming a slow-release reservoir. While HIV can develop resistance, studies show that mutations in the capsid significantly impair the virus's ability to replicate, making it a 'high cost' adaptation for the virus. This discovery opens doors for a new generation of durable HIV treatments.
Key Points
- The capsid is essential for protecting viral RNA and must remain largely unchanged for the virus to survive.
- Lenacapavir offers a long-acting treatment option (bi-annual injection) compared to daily oral pills.
- Viral resistance to capsid inhibitors comes at the cost of significantly reduced viral fitness and replication.
- This research provides a blueprint for targeting the protective shells of other viruses similarly.
Exam Facts
- Drug name: Lenacapavir (first capsid-based HIV inhibitor).
- Administration: Subcutaneous injection every six months.
- FDA approval date: June 18, 2025.
- Capsid: The protein shell that protects the virus's RNA.
Read it. Retain it. Recall it.
Get spaced-repetition flashcards, daily quizzes and offline access — free on Android.